THE PEPTIDE
What Is Thymosin Alpha-1? The Thymic Peptide, Explained
A short chain of 28 amino acids that the immune system uses as a tuning signal — what it is, where it comes from, and what it is not.
In plain English
What is Thymosin Alpha-1? It is a tiny natural protein — a peptide made of 28 amino acids (the building blocks proteins are assembled from). Your body makes it; it is linked to the thymus, the small gland behind the breastbone that trains immune cells. Its role is to help the immune system work properly: waking up defenses when they are weak, calming them when they are overactive. It is not a hormone for muscle or growth. The lab-made copy used in studies and abroad is called thymalfasin, and it is identical to the natural version. People sometimes call it the TA1 peptide or Tα1 for short. It is given as a small injection under the skin. Below, this page explains its structure, where it comes from in the body, and the molecules it is often confused with — all in plain language, with sources.
Thymosin alpha 1 peptide: structure and identity
The Thymosin Alpha-1 peptide is a 28-amino-acid, N-terminally acetylated polypeptide with a molecular weight of about 3108.3 daltons and the CAS number 62304-98-7 [1]. It is highly acidic, with no aromatic residues and no disulfide bonds, and its front-end acetyl cap is essential for biological activity. Goldstein and colleagues first isolated it from calf thymus — as a component of the crude preparation thymosin fraction 5 — and in 1977 determined its complete sequence, founding the field [1]. In the body it is not made directly; it is cleaved from a larger 113-amino-acid precursor called prothymosin alpha. Circulating levels decline with age and are reduced in some chronic inflammatory and autoimmune conditions. The absence of disulfide bonds and aromatic residues makes it an unusually simple, stable little molecule for its class, and the fact that the synthetic drug thymalfasin is sequence-identical means findings from the manufactured peptide and the natural one describe the same chemistry.
Thymalfasin: the synthetic drug name
Thymalfasin is the International Nonproprietary Name (INN) for the synthetic, sequence-identical version of Thymosin Alpha-1 used in clinical trials and marketed abroad. As a manufactured peptide it is chemically the same molecule as the endogenous one — the distinction is source, not structure. A comprehensive review notes that thymalfasin is approved in more than 35 countries, chiefly for chronic hepatitis B and as an immune adjuvant, and that it is usually well tolerated [4]. It is not approved for marketing in the United States, where availability is limited to investigational and compounding contexts. This site uses the generic naming throughout.
Ta1 peptide: what it is not
Because the naming is crowded, the TA1 peptide (Tα1) is routinely confused with other thymic peptides — so it helps to state what it is not. It is not a steroid and not an anabolic, growth, or performance compound; it is an immunomodulator. It is not thymosin beta-4 or its fragment TB-500 (a separate 43-amino-acid actin-binding peptide, and the WADA-prohibited one). It is not thymulin/FTS (a zinc-dependent nonapeptide), not thymopentin/TP-5 (a pentapeptide), and not thymalin (a separate bovine thymic-extract preparation). And it is not prothymosin alpha, which is its own larger precursor [1]. Same family of names, genuinely different molecules — different in sequence, size, and what they do. The confusion is not harmless: it is thymosin beta-4, not this peptide, that carries the doping-control implications, so getting the identity right has real consequences.
What the peptide is studied for
In the published literature, Thymosin Alpha-1 is studied chiefly as an immune modulator. Its longest and most consistent track record is in chronic hepatitis B, where adding it to oral antiviral therapy raised hepatitis B e-antigen seroconversion to 45.1% versus 15.2% for antiviral alone across pooled trials [10]. Beyond hepatitis, it has been investigated as an immune-restorative adjunct in sepsis (where the largest, most rigorous trial was null) [3], in severe COVID-19 (mixed evidence, with retrospective signals of reduced mortality not confirmed in pooled analysis) [6], and as an adjuvant in cancer care, framed as an immunostimulatory add-on rather than a primary therapy [14]. It has also appeared in vaccine-augmentation and HIV immune-reconstitution research [4]. The throughline is immunity, not metabolism or muscle.
The honest state of the evidence
The literature on this peptide is genuinely large — four decades of trials and broad international post-marketing use [4] — but it is also uneven, and a fair explainer has to say so. Many of the positive trials are single-region, open-label, or small, and meta-analyses repeatedly flag moderate-to-high risk of bias. The most rigorous test in any acute setting, the phase-3 TESTS sepsis trial, found no benefit [3]. So the accurate one-line summary is: a real, well-characterized immune peptide with its strongest evidence in chronic viral hepatitis, a benign safety profile in studied settings, and no US marketing approval — not a proven therapy for the wider range of uses it is sometimes promoted for.